Sotigalimab by Pyxis Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
Sotigalimab is under clinical development by Pyxis Oncology and currently in Phase I for Non-Small Cell Lung Cancer.
Source: pharmaceutical-technology.com
Page 10 - Pharmaceutical Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmaceutical Intelligence Today - Breaking & Trending Today
BPRDPO-56 by Molecular Targeting Technologies for Solid Tumor: Likelihood of Approval
BPRDPO-56 is under clinical development by Molecular Targeting Technologies and currently in Phase I for Solid Tumor.
Source: pharmaceutical-technology.com
ANG-003 by Anagram Therapeutics for Exocrine Pancreatic Insufficiency: Likelihood of Approval
ANG-003 is under clinical development by Anagram Therapeutics and currently in Phase I for Exocrine Pancreatic Insufficiency.
Source: pharmaceutical-technology.com
Anakinra by Swedish Orphan Biovitrum for Hospital Acquired Pneumonia (HAP): Likelihood of Approval
Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Hospital Acquired Pneumonia (HAP).
Source: pharmaceutical-technology.com
INCA-33890 by Incyte for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
INCA-33890 is under clinical development by Incyte and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.
Source: pharmaceutical-technology.com